Anne Thomas

10.5k citations

186 papers · 8.4k · 1 hit paper · h-index 48

Impact in

Oncology top 1%
- Colorectal Cancer Treatments and Studies
Hematology top 1%
- Hematopoietic Stem Cell Transplantation

Papers in

Oncology 57
- Colorectal Cancer Treatments and Studies 23
Cancer Research 13
- Cancer Genomics and Diagnostics 7

Co-authors: William P. Steward (22 shared papers)Judith Bard (2 shared papers)Edward A. Boyse (5 shared papers)Hal E. Broxmeyer (1 shared paper)Scott H. Cooper (1 shared paper)Denis K. English (1 shared paper)Giao Hangoc (1 shared paper)M. Arny (1 shared paper)
Journals: Annals of Oncology (16 papers)British Journal of Cancer (7 papers)European Journal of Cancer (6 papers)The Lancet Oncology (4 papers)Clinical Cancer Research (4 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

Anne Thomas

179 papers receiving 8k citations

Anne Thomas's Hit Papers

align trajectories log scale

Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. 1989 · 932 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

1989 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Anne Thomas

Since Specialization

Citations

This map shows the geographic impact of Anne Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Thomas more than expected).

Fields of papers citing papers by Anne Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Thomas. The network helps show where Anne Thomas may publish in the future.

Co-authors

The 25 scholars most cited alongside Anne Thomas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anne Thomas Line = papers co-authored together Anne Thomas links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 186 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proceedings of the National Academy of Sciences ·Hal E. Broxmeyer, G. W. Douglas, Giao Hangoc, Scott H. Cooper, Judith Bard, Denis K. English, M. Arny, Anne Thomas Hit paper breakdown →	1989	932
2	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies Journal of Clinical Oncology ·Bruno Morgan, Anne Thomas, Joachim Drevs, Jürgen Hennig, Martin Buechert, Asvina Jivan, Mark A. Horsfield, K. Mross	2003	553
3	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study The Lancet Oncology ·Timothy Jay Price, Marc Peeters, Tae Won Kim, Jin Li, Stefano Cascinu, Paul Ruff, Atilli Satya Suresh, Anne Thomas	2014	387
4	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial Cancer Discovery ·Alex Pearson, Elizabeth Catherine Smyth, Irina S. Babina, María Teresa Herrera-Abreu, Noelia Tarazona, Clare Peckitt, Elaine Kilgour, Neil R. Smith	2016	244
5	Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study The Lancet Oncology ·Timothy J. Iveson, Ross C. Donehower, Ірина Давиденко, Sergey A. Tjulandin, Andrzej Deptała, Mark Harrison, Sharanabasappa Somanath Nirni, Kuntegowdanahalli Chinnagiriyappa Lakshmaiah	2014	232
6	Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial The Lancet ·Martin S. Dennis, Gillian Elizabeth Mead, Catriona Graham, Maree Lisa Hackett, Graeme J. Hankey, Allan O. House, Steff Lewis, Erik Lundström	2018	217
7	Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial Journal of Nutrition ·Lynne M. Howells, Chinenye Iwuji, Glen R. B. Irving, Shaun R. Barber, Harriet S. Walter, Zahirah Sidat, Nicola Griffin-Teall, Raj Sukhbir Singh	2019	213
8	A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors Clinical Cancer Research ·Jordi A. Rodon, Hussein Abdul-Hassan Tawbi, Anne Thomas, Ronald G. Stoller, Christian P. Turtschi, José Baselga, John Sarantopoulos, Devalingam Mahalingam	2014	201
9	Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer Journal of Clinical Oncology ·Anne Thomas, Bruno Morgan, Mark A. Horsfield, Anthony Higginson, Andrea Kay, Lucy Lee, Eric Masson, Marie Puccio-Pick	2005	194
10	Familial Imprinting Determines H-2 Selective Mating Preferences Science ·K Yamazaki, Gary K. Beauchamp, DONNA KUPNIEWSKI, Judith Bard, Anne Thomas, E. A. Boyse	1988	191
11	Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery British Journal of Cancer ·Ian R. Powley, Meeta Patel, Gareth J. Miles, Howard Pringle, Lynne M. Howells, Anne Thomas, Catherine A. Kettleborough, Justin S. Bryans	2020	180
12	Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy Cancer Letters ·Mark I. James, Chinenye Iwuji, Glen R. B. Irving, Ankur Karmokar, Jennifer A. Higgins, Nicola Griffin-Teall, Anne Thomas, Peter Greaves	2015	158
13	Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study Investigational New Drugs ·Jens Samol, Malcolm Ranson, Edwina N. Scott, Euan Macpherson, James Carmichael, Anne Thomas +1 other	2011	142
14	Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anthony Mills, Gordon E. Crofoot, Cheryl McDonald, Peter Shalit, Jason Flamm, Joseph Gathe, Anita Scribner, David Shamblaw	2015	135
15	A Community‐Based Outbreak of Severe Respiratory Illness Caused by Human Adenovirus Serotype 14 The Journal of Infectious Diseases ·Paul F. Lewis, Mark A. Schmidt, Xiaoyan Lu, Dean D. Erdman, Mary B. Campbell, Anne Thomas, Paul R. Cieslak, LaDonna Grenz	2009	133
16	Human Adenovirus Associated with Severe Respiratory Infection, Oregon, USA, 2013–2014 Emerging infectious diseases ·Magdalena Kendall Scott, Christina Chommanard, Xiaoyan Lu, Dianna M. Appelgate, LaDonna Grenz, Eileen Schneider, Susan I. Gerber, Dean D. Erdman	2016	132
17	Expression of a complete and functional complement system by human neuronal cells in vitro International Immunology ·Anne Thomas, Philippe Gasque, David Vaudry, Bruno José Gonzalez, Marc Fontaine	2000	122
18	Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas European Journal of Nuclear Medicine and Molecular Imaging ·Norbert Galldiks, Lutz Kracht, Lothar Burghaus, Anne Thomas, Andreas H. Jacobs, Wolf–Dieter Heiss, Karl Herholz	2006	107
19	Active Bacterial Core Surveillance for Legionellosis — United States, 2011–2013 MMWR Morbidity and Mortality Weekly Report ·Kathleen L. Dooling, Karrie-Ann E. Toews, Lauri A. Hicks, Laurel E. Garrison, Brian Bachaus, Shelley M. Zansky, L. Rand Carpenter, Bill Schaffner	2015	107
20	Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials Annals of Oncology ·Joachim Drevs, Ute Zirrgiebel, C. Schmidt-Gersbach, Klaus B. Mross, Michael Medinger, L. Lee, José Cirı́aco Pinheiro, J M Wood	2005	104

About Anne Thomas

Anne Thomas is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Medicine and Hematology, having authored 186 papers that have together received 8.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (23 papers), Angiogenesis and VEGF in Cancer (9 papers), Curcumin's Biomedical Applications (8 papers), Blood properties and coagulation (8 papers), Gastric Cancer Management and Outcomes (8 papers), Cancer Genomics and Diagnostics (7 papers), Olfactory and Sensory Function Studies (6 papers) and Patient-Provider Communication in Healthcare (6 papers). The work is most often cited by research in Oncology (1.6k citations), Hematology (782 citations), Genetics (364 citations), Molecular Medicine (252 citations) and Sensory Systems (195 citations). Anne Thomas has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include William P. Steward, Judith Bard, Edward A. Boyse, Hal E. Broxmeyer, Scott H. Cooper, Denis K. English, Giao Hangoc, M. Arny, Bruno Morgan and Lynne M. Howells. Their work appears in journals such as Annals of Oncology, British Journal of Cancer, European Journal of Cancer, The Lancet Oncology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Anne Thomas

Impact in

Papers in i

In The Last Decade

Anne Thomas

Anne Thomas's Hit Papers

Peers

Countries citing papers authored by Anne Thomas

Fields of papers citing papers by Anne Thomas

All Works

About Anne Thomas

Explore authors with similar magnitude of impact

Papers in